Star Sports Medicine Co., Ltd. announced that Hang Seng Indexes Company Limited will add the company to the Hang Seng Composite Index, effective 7 September 2026. The decision follows the second-quarter 2026 review results released on 21 August 2026.
With index inclusion, Star Sports Medicine’s H-shares are expected to satisfy the eligibility thresholds for both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, potentially expanding the investor base accessible to the company.
The board highlighted that the milestone strengthens the group’s capital-market profile and supports long-term shareholder value creation. Management reiterated its strategic focus on product innovation, clinical-value enhancement and global expansion within the sports-medicine segment.
The announcement was authorised by Chairman and Executive Director Mr. Dong Wenxing on 24 August 2026. The board currently comprises two executive directors, five non-executive directors and four independent non-executive directors.